PDF herunterladen
Semin Liver Dis 2014; 34(01): 072-078
DOI: 10.1055/s-0034-1371012
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients

Mark S. Sulkowski
1   Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
29. April 2014 (online)

   Lizenzen und Reprints

Abstract

In the era of effective treatment for human immunodeficiency virus (HIV) infection, coinfection with hepatitis C virus (HCV) is an important cause of morbidity and mortality. Similar to other observations made in other HCV-infected patient populations, treatment of chronic HCV infection that results in sustained virologic response or eradication of the hepatitis infection has been strongly associated with decreased likelihood of end-stage liver disease and/or hepatocellular carcinoma and improved overall survival in HIV-infected patients. However, the effectiveness of HCV treatment has been limited due to frequent contraindications to interferon-α (INFα) and prior to the advent of HCV direct acting antivirals, relatively low rates of sustained virologic response. Since 2011, the efficacy of HCV treatment in coinfected patients has improved substantially with the addition of HCV direct-acting antivirals to INFα-based regimens. Based on these observations, there is mounting optimism that INFα-free, oral HCV treatments will further improve efficacy, and more importantly, increase access to treatment for many coinfected patients.

Keywords

human immunodeficiency virus - hepatitis C virus interferon - direct-acting antivirals - protease inhibitors - polymerase inhibitors - NS5A inhibitors
 

  • References

  • 1 van der Helm J, Geskus R, Sabin C , et al; CASCADE Collaboration in EuroCoord. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology 2013; 144 (4) 751-760 , e2
    CrossrefPubMedGoogle Scholar
  • 2 Wandeler G, Gsponer T, Bregenzer A , et al; Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55 (10) 1408-1416
    CrossrefPubMedGoogle Scholar
  • 3 Kirk GD, Mehta SH, Astemborski J , et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158 (9) 658-666
    CrossrefPubMedGoogle Scholar
  • 4 Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156 (4) 271-278
    CrossrefPubMedGoogle Scholar
  • 5 Kaplan JE, Benson C, Holmes KK , et al; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207 ; quiz CE1-4
    PubMedGoogle Scholar
  • 6 Rockstroh JK, Bhagani S, Benhamou Y , et al; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9 (2) 82-88
    CrossrefPubMedGoogle Scholar
  • 7 Torriani FJ, Rodriguez-Torres M, Rockstroh JK , et al; APRICOT Study Group. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351 (5) 438-450
    CrossrefPubMedGoogle Scholar
  • 8 Chung RT, Andersen J, Volberding P , et al; AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351 (5) 451-459
    CrossrefPubMedGoogle Scholar
  • 9 Rodriguez-Torres M, Slim J, Bhatti L , et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials 2012; 13 (3) 142-152
    CrossrefPubMedGoogle Scholar
  • 10 Limketkai BN, Mehta SH, Sutcliffe CG , et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308 (4) 370-378
    PubMedGoogle Scholar
  • 11 Berenguer J, Alvarez-Pellicer J, Martín PM , et al; GESIDA3603/5607 Study Group. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50 (2) 407-413
    CrossrefPubMedGoogle Scholar
  • 12 Mehta SH, Genberg BL, Astemborski J , et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33 (3) 126-133
    CrossrefPubMedGoogle Scholar
  • 13 Mehta SH, Lucas GM, Mirel LB , et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20 (18) 2361-2369
    CrossrefPubMedGoogle Scholar
  • 14 Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther 2006; 24 (4) 585-591
    CrossrefPubMedGoogle Scholar
  • 15 Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012; 56 (2) 320-325
    CrossrefPubMedGoogle Scholar
  • 16 Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012; 142 (6) 1324-1334 , e3
    CrossrefPubMedGoogle Scholar
  • 17 Cacoub P, Rosenthal E, Halfon P, Sene D, Perronne C, Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepat 2006; 13 (10) 678-682
    CrossrefPubMedGoogle Scholar
  • 18 McGowan CE, Monis A, Bacon BR , et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013; 57 (4) 1325-1332
    CrossrefPubMedGoogle Scholar
  • 19 Jacobson IM, McHutchison JG, Dusheiko G , et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25) 2405-2416
    CrossrefPubMedGoogle Scholar
  • 20 Poordad F, McCone Jr J, Bacon BR , et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13) 1195-1206
    CrossrefPubMedGoogle Scholar
  • 21 Lawitz E, Mangia A, Wyles D , et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20) 1878-1887
    CrossrefPubMedGoogle Scholar
  • 22 Jacobson IM, Gordon SC, Kowdley KV , et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20) 1867-1877
    CrossrefPubMedGoogle Scholar
  • 23 Sulkowski MS, Gardiner DF, Rodriguez-Torres M , et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370 (3) 211-221
    CrossrefPubMedGoogle Scholar
  • 24 Kowdley KV, Lawitz E, Poordad F , et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370 (3) 222-232
    CrossrefPubMedGoogle Scholar
  • 25 Kane M, Yadav SS, Bitzegeio J , et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 2013; 502 (7472) 563-566
    CrossrefPubMedGoogle Scholar
  • 26 Lane HC, Davey V, Kovacs JA , et al. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Ann Intern Med 1990; 112 (11) 805-811
    CrossrefPubMedGoogle Scholar
  • 27 Asmuth DM, Murphy RL, Rosenkranz SL , et al; AIDS Clinical Trials Group A5192 Team. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201 (11) 1686-1696
    CrossrefPubMedGoogle Scholar
  • 28 Sulkowski MS, Cooper C, Hunyady B , et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8 (4) 212-223
    CrossrefPubMedGoogle Scholar
  • 29 Sherman KE, Shire NJ, Rouster SD , et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128 (2) 313-327
    CrossrefPubMedGoogle Scholar
  • 30 Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994; 84 (4) 1020-1023
    PubMedGoogle Scholar
  • 31 Daar ES, Lynn H, Donfield S , et al; Hemophilia Growth and Development Study. Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. J Infect Dis 2001; 183 (4) 589-595
    CrossrefPubMedGoogle Scholar
  • 32 Thomas DL, Shih JW, Alter HJ , et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174 (4) 690-695
    CrossrefPubMedGoogle Scholar
  • 33 Balagopal A , et al. Antiretroviral therapy, Interferon Sensitivity, and Virologic Set Point in HIV-Hepatitis C Virus Co-infected Patients. Hepatology 2014; ; In press
    PubMedGoogle Scholar
  • 34 Hadziyannis SJ, Sette Jr H, Morgan TR , et al; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5) 346-355
    CrossrefPubMedGoogle Scholar
  • 35 Sulkowski M, Pol S, Mallolas J , et al; P05411 study investigators. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13 (7) 597-605
    CrossrefPubMedGoogle Scholar
  • 36 Sulkowski MS, Sherman KE, Dieterich DT , et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159 (2) 86-96
    PubMedGoogle Scholar
  • 37 Dieterich DT , et al. Simeprevir (TMC435) plus peginterferon/ribavirin in patients co-infected with HCV genotype-1 andHIV-1: primary analysis of the C212 study. 14th European AIDs Conference (EACS 2013). Brussels. October 16–19, 2013. Abstract PS9/5.
    PubMed
  • 38 Jacobson I , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Paper presented at: 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, Netherlands
    PubMed
  • 39 Manns M , et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection n treatment-naïve patients: results from QUEST-2, a phase III trial. Paper presented at: 48th Annual Meeting of the European Association for the Study of the Liver; April 24–28, 2013; Amsterdam, Netherlands
    PubMed
  • 40 Rodriguez-Torres M , et al. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1–4 HCV infected patients who are HIV coinfected with HIV. Paper presented at: ID Week 2013; October 2–6, 2013; San Francisco, CA
    PubMed
  • 41 Sulkowski MS , et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Paper presented at: The 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1–5, 2013; Washington, DC
    PubMed
  • 42 Osinusi A, Meissner EG, Lee YJ , et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310 (8) 804-811
    CrossrefPubMedGoogle Scholar
  • 43 van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther 2013; 18 (4) 553-560
    CrossrefPubMedGoogle Scholar
  • 44 Seden K, Back D, Khoo S. Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009; 64 (1) 5-8
    CrossrefPubMedGoogle Scholar
  • 45 Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11 (2) 179-185
    PubMedGoogle Scholar
  • 46 Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs 2013;
    PubMedGoogle Scholar
  • 47 Asselah T. ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. J Hepatol 2013; 59 (4) 885-888
    CrossrefPubMedGoogle Scholar
  • 48 Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Direct-acting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2013;
    PubMedGoogle Scholar
  • 49 Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. J Int AIDS Soc 2011; 14: 22
    CrossrefPubMedGoogle Scholar
  • 50 von Schoen-Angerer T, Cohn J, Swan T, Piot P. UNITAID can address HCV/HIV co-infection. Lancet 2013; 381 (9867) 628
    CrossrefPubMedGoogle Scholar